Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,519 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma.
Merchant TE, Kun LE, Krasin MJ, Wallace D, Chintagumpala MM, Woo SY, Ashley DM, Sexton M, Kellie SJ, Ahern V, Gajjar A. Merchant TE, et al. Among authors: wallace d. Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):782-7. doi: 10.1016/j.ijrobp.2007.07.2342. Epub 2007 Sep 24. Int J Radiat Oncol Biol Phys. 2008. PMID: 17892918 Free PMC article. Clinical Trial.
Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma.
Mulhern RK, Palmer SL, Merchant TE, Wallace D, Kocak M, Brouwers P, Krull K, Chintagumpala M, Stargatt R, Ashley DM, Tyc VL, Kun L, Boyett J, Gajjar A. Mulhern RK, et al. Among authors: wallace d. J Clin Oncol. 2005 Aug 20;23(24):5511-9. doi: 10.1200/JCO.2005.00.703. J Clin Oncol. 2005. PMID: 16110011
Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial.
Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, Fouladi M, Broniscer A, Krance R, Hale GA, Stewart CF, Dauser R, Sanford RA, Fuller C, Lau C, Boyett JM, Wallace D, Gilbertson RJ. Gajjar A, et al. Among authors: wallace d. Lancet Oncol. 2006 Oct;7(10):813-20. doi: 10.1016/S1470-2045(06)70867-1. Lancet Oncol. 2006. PMID: 17012043 Clinical Trial.
Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.
Fouladi M, Chintagumpala M, Ashley D, Kellie S, Gururangan S, Hassall T, Gronewold L, Stewart CF, Wallace D, Broniscer A, Hale GA, Kasow KA, Merchant TE, Morris B, Krasin M, Kun LE, Boyett JM, Gajjar A. Fouladi M, et al. Among authors: wallace d. J Clin Oncol. 2008 Aug 1;26(22):3749-55. doi: 10.1200/JCO.2007.14.3974. J Clin Oncol. 2008. PMID: 18669462 Free PMC article. Clinical Trial.
A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET.
Chintagumpala M, Hassall T, Palmer S, Ashley D, Wallace D, Kasow K, Merchant TE, Krasin MJ, Dauser R, Boop F, Krance R, Woo S, Cheuk R, Lau C, Gilbertson R, Gajjar A. Chintagumpala M, et al. Among authors: wallace d. Neuro Oncol. 2009 Feb;11(1):33-40. doi: 10.1215/15228517-2008-079. Epub 2008 Sep 16. Neuro Oncol. 2009. PMID: 18796696 Free PMC article.
Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor.
Stewart CF, Iacono LC, Chintagumpala M, Kellie SJ, Ashley D, Zamboni WC, Kirstein MN, Fouladi M, Seele LG, Wallace D, Houghton PJ, Gajjar A. Stewart CF, et al. Among authors: wallace d. J Clin Oncol. 2004 Aug 15;22(16):3357-65. doi: 10.1200/JCO.2004.10.103. J Clin Oncol. 2004. PMID: 15310781 Clinical Trial.
3,519 results